"The first reaction you get is - you can't orally deliver a natural peptide can you? The response I give them - you bet we can!! We are taking over 30 years of home grown, peptide-related inventions, know-how and expertise and placing our validated technologies into multiple development programs to enhance the game changing power of our partners' peptide."
- Greg Mayes, Chief Business Officer

"I am proud to have been part of the team that developed our proprietary, innovative platform technologies for oral delivery and recombinant expression of peptides, and their application to our therapeutic programs. The new Unigene now brings in an aggressive business focus, vision, and strategic realignment that enables us to apply our technologies to a much wider range of peptide molecules and closer to fulfilling the promise of our scientific achievements for the benefit of patients, our investors, and our employees alike."
- Nozer Mehta, VP, Research and Development

"The recent Biologics Price Competition and Innovation Act has created a new landscape for the development of peptide therapies. Unigene's new targeted growth strategy places us in an excellent position to maximize this opportunity, and deliver oral agents to patients by building on our proven track record of registration success and excellence in quality systems."
- Roxanne Tavakkol, VP, Global Regulatory Affairs and Quality Assurance

"Unigene truly has a distinctive competence when it comes to the design and formulation of orally delivered therapeutic peptides. By that, I mean we possess unique capabilities that allow us to make inroads into target markets gaining advantage over competitors. When we license our Peptelligence™ technology platforms to our partners, we pass on our distinctive competence to them, in turn enabling these companies to perform better than their competitors. As such, Unigene truly is a peptide powerhouse and the partner of choice in the therapeutic market space!"
- Ashleigh Palmer, President and CEO

"Unigene represents a compelling investment opportunity. The Company now has a targeted growth strategy, an experienced management team focused on delivering results and multiple events that could fundamentally change the Company over the course of the next 6-12 months."